| Oct 31 |
Esperion Therapeutics (ESPR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
|
| Oct 31 |
Esperion Announces a Featured Presentation in the Late Breaker/Featured Science Track and Three Poster Presentations Accepted for the 2024 American Heart Association (AHA) Scientific Sessions
|
| Oct 24 |
Esperion to Report Third Quarter 2024 Financial Results on November 7
|
| Oct 17 |
Millennium Management LLC's Strategic Reduction in Esperion Therapeutics Inc Holdings
|
| Oct 3 |
Is Esperion Therapeutics, Inc. (ESPR) the Best NASDAQ Stock Under $5?
|
| Oct 2 |
Esperion EU Partner Reports Final Real-World Results from MILOS German Cohort Demonstrating Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
|
| Sep 25 |
Esperion Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
|
| Sep 11 |
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
|
| Sep 5 |
Esperion to Participate in Upcoming 2024 Cantor Global Healthcare Conference
|
| Sep 3 |
Esperion Secures Additional Commercial and Medicare Formulary Coverage for NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe)
|
